Cure8 research brief
Knowing ustekinumab levels and anti-drug antibody status may help predict which people with Crohn’s disease are more likely to be in clinical remission and guide treatment adjustments.
Adults with Crohn’s disease on ustekinumab, clinicians who manage biologic dosing, and researchers studying therapeutic drug monitoring or biologic optimization.
This single-center cross-sectional study measured ustekinumab trough levels (TL) and anti-drug antibodies at the pre-dose visit in 76 adults on maintenance therapy ≥24 weeks. Patients were grouped by whether they met a target trough level (≥1 µg/mL). Remission was more common in patients who reached the target TL (78% vs 29%).
Based on TL, ADA status, and disease activity the investigators recommended continuing current dosing for some patients, shortening the dosing interval or escalating therapy for others, and switching biologics for a subset.
Practical takeaways The report supports that measuring ustekinumab levels and antibodies can inform individualized treatment decisions (continue, escalate/shorten interval, or switch biologic). This study is a cross-sectional, single-center real-world analysis and describes associations rather than proving causation.
This is a single-center, cross-sectional study measuring associations at one pre-dose visit; it does not establish causality or long-term outcomes. The structured content depth is an abstract from the journal and Cure8 did not review full trial records beyond the provided text.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
